Cynata Therapeutics Limited (CYYNF)
USD 0.3
(117.39%)
USD 0.3
(117.39%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -6.2 Million AUD | 61.62% |
| 2023 | -16.16 Million AUD | 32.06% |
| 2022 | -23.79 Million AUD | 10.92% |
| 2021 | -26.71 Million AUD | -95.73% |
| 2020 | -13.64 Million AUD | -95.63% |
| 2019 | -6.97 Million AUD | 42.84% |
| 2018 | -12.2 Million AUD | -17.94% |
| 2017 | -10.34 Million AUD | -112.12% |
| 2016 | -4.87 Million AUD | -4.46% |
| 2015 | -4.67 Million AUD | 8.31% |
| 2014 | -5.09 Million AUD | -356.26% |
| 2013 | -1.11 Million AUD | -12.44% |
| 2012 | -993.07 Thousand AUD | -168.96% |
| 2011 | -369.23 Thousand AUD | 41.17% |
| 2010 | -627.61 Thousand AUD | 37.55% |
| 2009 | -1 Million AUD | 51.67% |
| 2008 | -2.07 Million AUD | 35.98% |
| 2007 | -3.24 Million AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q4 | -6.2 Million AUD | 0.0% |
| 2024 FY | -6.2 Million AUD | 61.62% |
| 2024 Q2 | -11.16 Million AUD | 0.0% |
| 2024 Q1 | -11.16 Million AUD | 53.08% |
| 2023 Q2 | -16.41 Million AUD | 0.0% |
| 2023 Q3 | -16.16 Million AUD | 1.49% |
| 2023 FY | -16.16 Million AUD | 32.06% |
| 2023 Q4 | -23.79 Million AUD | -47.2% |
| 2023 Q1 | -16.41 Million AUD | 31.04% |
| 2022 Q1 | -26.78 Million AUD | -0.26% |
| 2022 Q2 | -26.78 Million AUD | 0.0% |
| 2022 Q3 | -23.79 Million AUD | 11.16% |
| 2022 FY | -23.79 Million AUD | 10.92% |
| 2022 Q4 | -23.79 Million AUD | 0.0% |
| 2021 Q2 | -24.91 Million AUD | 0.0% |
| 2021 FY | -26.71 Million AUD | -95.73% |
| 2021 Q3 | -26.71 Million AUD | -7.21% |
| 2021 Q4 | -26.71 Million AUD | 0.0% |
| 2021 Q1 | -24.91 Million AUD | -82.57% |
| 2020 FY | -13.64 Million AUD | -95.63% |
| 2020 Q1 | -5.91 Million AUD | 15.18% |
| 2020 Q2 | -5.91 Million AUD | 0.0% |
| 2020 Q4 | -13.64 Million AUD | 0.0% |
| 2020 Q3 | -13.64 Million AUD | -130.64% |
| 2019 Q2 | -10.63 Million AUD | 0.0% |
| 2019 Q1 | -10.63 Million AUD | 12.83% |
| 2019 Q3 | -6.97 Million AUD | 34.42% |
| 2019 FY | -6.97 Million AUD | 42.84% |
| 2019 Q4 | -6.97 Million AUD | 0.0% |
| 2018 Q4 | -12.2 Million AUD | 0.0% |
| 2018 FY | -12.2 Million AUD | -17.94% |
| 2018 Q3 | -12.2 Million AUD | -38.09% |
| 2018 Q2 | -8.83 Million AUD | 0.0% |
| 2018 Q1 | -8.83 Million AUD | 14.6% |
| 2017 Q2 | -3.91 Million AUD | 0.0% |
| 2017 FY | -10.34 Million AUD | -112.12% |
| 2017 Q4 | -10.34 Million AUD | 0.0% |
| 2017 Q3 | -10.34 Million AUD | -164.41% |
| 2017 Q1 | -3.91 Million AUD | 19.78% |
| 2016 Q1 | -6.36 Million AUD | -36.31% |
| 2016 Q3 | -4.87 Million AUD | 23.37% |
| 2016 Q2 | -6.36 Million AUD | 0.0% |
| 2016 FY | -4.87 Million AUD | -4.46% |
| 2016 Q4 | -4.87 Million AUD | 0.0% |
| 2015 FY | -4.67 Million AUD | 8.31% |
| 2015 Q4 | -4.67 Million AUD | 0.0% |
| 2015 Q3 | -4.67 Million AUD | 24.13% |
| 2015 Q1 | -6.15 Million AUD | -20.84% |
| 2015 Q2 | -6.15 Million AUD | 0.0% |
| 2014 FY | -5.09 Million AUD | -356.26% |
| 2014 Q4 | -5.09 Million AUD | 0.0% |
| 2014 Q3 | -5.09 Million AUD | 17.83% |
| 2014 Q2 | -6.2 Million AUD | 0.0% |
| 2014 Q1 | -6.2 Million AUD | -455.28% |
| 2013 Q4 | -1.11 Million AUD | 0.0% |
| 2013 Q3 | -1.11 Million AUD | 0.0% |
| 2013 FY | -1.11 Million AUD | -12.44% |
| 2012 Q4 | -993.07 Thousand AUD | 0.0% |
| 2012 FY | -993.07 Thousand AUD | -168.96% |
| 2011 Q4 | -369.23 Thousand AUD | 0.0% |
| 2011 FY | -369.23 Thousand AUD | 41.17% |
| 2010 Q4 | -627.61 Thousand AUD | 0.0% |
| 2010 FY | -627.61 Thousand AUD | 37.55% |
| 2009 FY | -1 Million AUD | 51.67% |
| 2009 Q4 | -1 Million AUD | 0.0% |
| 2008 FY | -2.07 Million AUD | 35.98% |
| 2008 Q4 | -2.07 Million AUD | 0.0% |
| 2007 FY | -3.24 Million AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 42.79 Million USD | 114.501% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 209.862% |
| CSL Limited | 10.52 Billion USD | 100.059% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 1.572% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1076.974% |
| BioStem Technologies, Inc. | 4.47 Million USD | 238.761% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 130.605% |
| Qrons Inc. | 351.42 Thousand USD | 1865.777% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -2385.946% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 114.287% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 148.455% |
| Skye Bioscience, Inc. | -5.72 Million USD | -8.46% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -30306.791% |
| Rebus Holdings, Inc. | 305 Thousand USD | 2134.563% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 31334.801% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -473596.031% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.415% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 1097.072% |
| Adynxx, Inc. | - USD | Infinity% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 139.367% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 250.689% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 1644.216% |
| SQZ Biotechnologies Company | -36.23 Million USD | 82.876% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 376.752% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 769.274% |
| Mesoblast Limited | 55.85 Million USD | 111.109% |
| Marizyme, Inc. | 18.56 Million USD | 133.418% |
| Genus plc | 190.6 Million USD | 103.256% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 377.544% |
| Pharming Group N.V. | 109.8 Million USD | 105.651% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 821.358% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 611.202% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 1012.561% |
| ContraFect Corporation | -6.02 Million USD | -2.977% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 4708.931% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 637.066% |
| IMV Inc. | 7.67 Million USD | 180.9% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 212.787% |
| MultiCell Technologies, Inc. | 90.04 USD | 6891945.846% |
| ONE Bio Corp. | 9.04 Million USD | 168.644% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -745.45% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 147.933% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 553.622% |
| Q BioMed Inc. | 4.06 Million USD | 252.843% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 120.31% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 715.79% |
| Biomind Labs Inc. | 711.4 Thousand USD | 972.28% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 110.249% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 410.365% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 1825.117% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 4538.656% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 381.811% |
| GB Sciences, Inc. | 1.74 Million USD | 455.14% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -3276.4% |
| HST Global, Inc. | 96.79 Thousand USD | 6511.019% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 3109.169% |
| Halberd Corporation | 144.72 Thousand USD | 4387.849% |
| Enzolytics Inc. | 981.65 Thousand USD | 732.138% |
| Agentix Corp. | 37.63 Thousand USD | 16590.176% |
| Resverlogix Corp. | 6.45 Million USD | 196.193% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -821.931% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 99.694% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 86.8% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 187.759% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 329.099% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 29.802% |
| AVAX Technologies, Inc. | -5.9 Million USD | -5.119% |
| Zenith Capital Corp. | 10.06 Thousand USD | 61759.559% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 3196.022% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 360.072% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 3872.084% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -33776.067% |
| Kadimastem Ltd | -253.1 Thousand USD | -2351.746% |
| Helix BioMedix, Inc. | -2.57 Million USD | -141.453% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 3183.376% |
| LadRx Corporation | -2.03 Million USD | -204.715% |
| Cell Source, Inc. | 9.23 Million USD | 167.217% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1076.974% |
| NovAccess Global Inc. | 2.17 Million USD | 384.853% |
| Affymax, Inc. | -5.59 Million USD | -10.87% |
| Itoco Inc. | 228.3 Thousand USD | 2818.039% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 4663.176% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 225.185% |
| Mobile Lads Corp. | 484.23 Thousand USD | 1381.497% |
| CytoDyn Inc. | 20.26 Million USD | 130.626% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -959006.337% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -66852.852% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 180.527% |
| SYBLEU INC | 473.71 Thousand USD | 1409.95% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 239.228% |
| International Stem Cell Corporation | 2.59 Million USD | 339.591% |
| Bioxytran, Inc. | 1.89 Million USD | 426.788% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 10042.509% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 384.535% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 280.705% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 172.553% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 903.179% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -396.433% |
| Neutra Corp. | 52.18 Thousand USD | 11990.735% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -149.314% |
| PureTech Health plc | -167.19 Million USD | 96.289% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -2433.775% |
| IXICO plc | -4.44 Million USD | -39.617% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 146.943% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 111.313% |
| CSL Limited | 10.52 Billion USD | 100.059% |
| Cellectis S.A. | -43.81 Million USD | 85.838% |